Oxford Biomedica PLC
01 November 2002
1 November 2002
For further information, please contact:
Oxford BioMedica plc
Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000
Beattie Financial - City/Financial Enquiries
Mike Wort / James Chandler Tel: +44 (0)20 7398 3300
Charles Consultants - Scientific/Trade Press Enquiries:
Sue Charles, Katja Stout Tel: +44 (0)20 7321 3870
OXFORD BIOMEDICA PLC
RESIGNATION OF BOARD MEMBER
Oxford, United Kingdom - 1 November 2002.
The Board of Oxford BioMedica plc (LSE:OXB) announces that it has accepted the
resignation of Dr Neill MacKenzie, Executive Director and Senior Vice President
for Business Development, at its board meeting today.
Dr MacKenzie is leaving to pursue his career elsewhere in the biotechnology
industry. The Board thanks him for his significant contribution and wishes him
well for the future.
-Ends-
Notes to Editors
1. Oxford BioMedica plc
Established in 1995 as a spin out from Oxford University, Oxford BioMedica
is an international biotechnology company with a diverse portfolio of
products and technology, specialising in gene-based products and technology
in the areas of cancer, neurological disease, cardiovascular disease and
blood disorders. This is underpinned by over 70 patent families, about
quarter of which are issued. Oxford BioMedica plc was floated on the
Alternative Investment Market of the London Stock Exchange in December
1996, and was promoted to the United Kingdom Listing Authority Official
List in April 2001 following a successful £35.5 million fund-raising.
Oxford BioMedica is headquartered in Oxford, UK and has a wholly-owned
subsidiary in San Diego, USA
Currently Oxford BioMedica has corporate collaborations with Aventis, IDM,
Amersham, Valentis, Virbac and Wyeth. BioMedica has two products in Phase
I/II clinical trials: MetXia(R) for late-stage breast cancer, and TroVax(R)
for late-stage colorectal cancer.
2. World Wide Web
Further information is available on the World Wide Web at http://
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.